BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 26045824)

  • 1. High expression of E-cadherin in pleural effusion cells predicts better prognosis in lung adenocarcinoma patients.
    Zhao C; Li X; Su C; Li J; Cheng N; Ren S; Chen X; Zhou C
    Int J Clin Exp Pathol; 2015; 8(3):3104-9. PubMed ID: 26045824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epithelial mesenchymal transition (EMT) and non-small cell lung cancer (NSCLC): a mutual association with airway disease.
    Mahmood MQ; Ward C; Muller HK; Sohal SS; Walters EH
    Med Oncol; 2017 Mar; 34(3):45. PubMed ID: 28197929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epithelial phenotype as a predictive marker for response to EGFR-TKIs in non-small cell lung cancer patients with wild-type EGFR.
    Ren S; Su C; Wang Z; Li J; Fan L; Li B; Li X; Zhao C; Wu C; Hou L; He Y; Gao G; Chen X; Ren J; Li A; Xu G; Zhou X; Zhou C; Schmid-Bindert G
    Int J Cancer; 2014 Dec; 135(12):2962-71. PubMed ID: 24771540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The EMT status in the primary tumor does not predict postoperative recurrence or disease-free survival in lung adenocarcinoma.
    Chikaishi Y; Uramoto H; Tanaka F
    Anticancer Res; 2011 Dec; 31(12):4451-6. PubMed ID: 22199314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of EGFR mutation status in lung adenocarcinoma specimens with different proportions of tumor cells using two methods of differential sensitivity.
    Han HS; Lim SN; An JY; Lee KM; Choe KH; Lee KH; Kim ST; Son SM; Choi SY; Lee HC; Lee OJ
    J Thorac Oncol; 2012 Feb; 7(2):355-64. PubMed ID: 22157369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung.
    Kim S; Koh J; Kim MY; Kwon D; Go H; Kim YA; Jeon YK; Chung DH
    Hum Pathol; 2016 Dec; 58():7-14. PubMed ID: 27473266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma.
    Uramoto H; Shimokawa H; Hanagiri T; Kuwano M; Ono M
    Lung Cancer; 2011 Sep; 73(3):361-5. PubMed ID: 21315472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of biological markers of epithelial to mesenchymal transition in oesophageal adenocarcinoma, an immunohistochemical study.
    Prins MJ; Ruurda JP; Lolkema MP; Sitarz R; Ten Kate FJ; van Hillegersberg R
    J Clin Pathol; 2015 Jul; 68(7):529-35. PubMed ID: 25855799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epithelial-mesenchymal transition in patients of pulmonary adenocarcinoma: correlation with cancer stem cell markers and prognosis.
    Sung WJ; Park KS; Kwak SG; Hyun DS; Jang JS; Park KK
    Int J Clin Exp Pathol; 2015; 8(8):8997-9009. PubMed ID: 26464642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of EGFR mutation rates in lung adenocarcinoma tissue and pleural effusion samples.
    Guan Y; Wang ZJ; Wang LQ; Hua DF; Liu J
    Genet Mol Res; 2016 Apr; 15(2):. PubMed ID: 27173189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EMT markers in lung adenocarcinoma pleural effusion spheroid cells.
    Giarnieri E; De Vitis C; Noto A; Roscilli G; Salerno G; Mariotta S; Ricci A; Bruno P; Russo G; Laurenzi A; Giovagnoli MR; Ciliberto G; Mancini R
    J Cell Physiol; 2013 Aug; 228(8):1720-6. PubMed ID: 23255165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alteration of the E-cadherin/β-catenin complex predicts poor response to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment.
    Yoo SB; Kim YJ; Kim H; Jin Y; Sun PL; Jheon S; Lee JS; Chung JH
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S545-52. PubMed ID: 23579873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR.
    Wu SG; Kuo YW; Chang YL; Shih JY; Chen YH; Tsai MF; Yu CJ; Yang CH; Yang PC
    J Thorac Oncol; 2012 Jan; 7(1):98-104. PubMed ID: 22124476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of epithelial-mesenchymal transition and IGF-1R expression in prediction of gefitinib activity as the second-line treatment for advanced nonsmall-cell lung cancer.
    Chen B; Xiao F; Li B; Xie B; Zhou J; Zheng J; Zhang W
    Cancer Invest; 2013 Aug; 31(7):454-60. PubMed ID: 23915069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct sequencing and amplification refractory mutation system for epidermal growth factor receptor mutations in patients with non-small cell lung cancer.
    Chu H; Zhong C; Xue G; Liang X; Wang J; Liu Y; Zhao S; Zhou Q; Bi J
    Oncol Rep; 2013 Nov; 30(5):2311-5. PubMed ID: 24002698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer.
    Zhou J; Wang J; Zeng Y; Zhang X; Hu Q; Zheng J; Chen B; Xie B; Zhang WM
    Oncotarget; 2015 Dec; 6(42):44332-45. PubMed ID: 26554308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epithelial-Mesenchymal Transition in Non Small-cell Lung Cancer.
    Tsoukalas N; Aravantinou-Fatorou E; Tolia M; Giaginis C; Galanopoulos M; Kiakou M; Kostakis ID; Dana E; Vamvakaris I; Korogiannos A; Tsiambas E; Salemis N; Kyrgias G; Karameris A; Theocharis S
    Anticancer Res; 2017 Apr; 37(4):1773-1778. PubMed ID: 28373440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of epithelial-mesenchymal transition markers with clinicopathologic parameters in adenocarcinomas and squamous cell carcinoma of the lung.
    Kim SH; Kim JM; Shin MH; Kim CW; Huang SM; Kang DW; Suh KS; Yi ES; Kim KH
    Histol Histopathol; 2012 May; 27(5):581-91. PubMed ID: 22419022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency of EGFR mutations in lung adenocarcinoma with malignant pleural effusion: Implication of cancer biological behaviour regulated by EGFR mutation.
    Zou J; Bella AE; Chen Z; Han X; Su C; Lei Y; Luo H
    J Int Med Res; 2014 Oct; 42(5):1110-7. PubMed ID: 25239875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients.
    Yauch RL; Januario T; Eberhard DA; Cavet G; Zhu W; Fu L; Pham TQ; Soriano R; Stinson J; Seshagiri S; Modrusan Z; Lin CY; O'Neill V; Amler LC
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8686-98. PubMed ID: 16361555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.